Adjuvant Osimertinib Exceeds Expectations in EGFR-Positive NSCLC – The ASCO Post

By Alice Goodman Posted: 5/28/2020 5:30:00 PM Last Updated: 5/29/2020 3:49:14 PM Adjuvant osimertinib significantly improved disease-free survival compared with placebo in patients with stage IB to IIIA ­EGFR-mutated non–small cell lung cancer (NSCLC) who underwent complete…

Read the full article here

Related Articles